Phenotypes of chronic obstructive pulmonary disease and the ECLIPSE study: preliminary results
https://doi.org/10.18093/0869-0189-2011-0-3-113-117
Abstract
Phenotypes of chronic obstructive pulmonary disease and the ECLIPSE study: preliminary results.
About the Author
S. I. Ovcharenko
ГОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова"
Russian Federation
Russian Federation
References
1. Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких. (Федеральная программа): Практическое руководство для врачей. 2-е изд. М.; 2004.
2. Buist S., McBurnie, Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.
3. Celli B.R., MacNee W., Agusti A.G. et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
4. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176 (6): 532–555.
5. Committee for proprietary medicinal products points to consider on clinical investigation of medicine products in the chronic treatment of patients with COPD. London; 1999. 562–598.
6. Jones P.W., Agusti A. Outcomes and markers of chronic obstructive pulmonary disease. Eur. Resp. J. 2006; 27: 822–832.
7. Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416–469.
8. Han MeiLan K., Agusti A., Calverely P. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 598–604.
9. Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких. M.: Атмосфера; 2008.
10. Овчаренко С.И., Капустина В.А. Хроническая обструктивная болезнь легких: особенности у женщин. Пульмонология 2009; 2: 102–112.
11. Vestbo J., Anderson W., Coxson H.O. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoint (ECLIPSE). Eur. Respir. J. 2008; 31: 869–873.
12. Agusti A., Calverely P., Celli B. et al. Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
13. Kanner R.E., Anthonisen N.R., Connett J.E. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 358–364.
14. Donaldson G.C., Seemungal T.A., Bhowmik A. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.
15. Donaldson G.C., Wilkinson T.M.A., Hurst J.R. et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 446–452.
16. Seemungal T.A., Donaldson G.C, Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157 (5, Pt 1): 1418–1422.
17. Soler5Cataluna J.J., Martinez5Garcia M.A., Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–931.
18. Sullivan S.D., Ramsey S.D., Lee T.A. The economic burden of COPD*. Chest 2000; 117 (2, Suppl.): 5S–9S.
19. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.
Review
For citations:
Ovcharenko S.I. Phenotypes of chronic obstructive pulmonary disease and the ECLIPSE study: preliminary results. PULMONOLOGIYA. 2011;(3):113-117. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-3-113-117
Views:
835
Email this article 